Scholarlink

Purpose <p>Personalized therapy in acromegaly is limited by interindividual variability in drug responses and the lack of robust markers predicting tumor shrinkage, rather than biochemical control alone. To test whether <i>ex vivo</i> drug-induced viability changes in patient-derived 3D cultures (Pd3D) of GH–secreting pituitary adenomas reflect tumor cell-intrinsic pharmacological sensitivity and align with established clinical predictors.</p> Methods <p>Spheroid-based Pd3D cultures were established from 27 patients with acromegaly. Cultures were exposed to octreotide, cabergoline, pasireotide, or vehicle control. We assessed cell viability changes; sample-level responder status (viability reduction <i>vs</i> vehicle, <i>p</i> &lt; 0.05); and associations between responder status and known predictive markers, including clinical characteristics, MRI findings, dynamic drug tests, and pathological features. In 6 cases, AI-based digital image analysis quantified pre- and post-treatment SSTR2 expression in liquid-based cytology (LBC).</p> Results <p>All agents modestly reduced median cell viability (84–86%, <i>p</i> &lt; 0.05), with responder rates of 33–40%. Concordance with established predictors was observed: octreotide responders correlated with T2 hypointensity (88% <i>vs</i> 44%, <i>p</i> = 0.04); cabergoline with positive bromocriptine tests (100% <i>vs</i> 45%, <i>p</i> = 0.03); and pasireotide with sparsely granulated patterns (64% <i>vs</i> 19%, <i>p</i> = 0.04). AI-based dynamic analysis demonstrated that <i>ex vivo</i> responders showed relatively stable SSTR2 expression after treatment, whereas nonresponders exhibited marked depletion.</p> Conclusion <p>Spheroid-based Pd3D <i>ex vivo</i> viability assays revealed modest but significant cohort-level effects and sample-level concordance with clinical predictors, suggesting its potential utility as an exploratory model. Additionally, AI-based quantification of SSTR2 dynamics captured functional receptor shifts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ex Vivo drug sensitivity in patient-derived 3D cultures in acromegaly and its association with clinical predictors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月24日

查看全文
  • Yasutaka Tsujimoto,
  • Atsushi Ishida,
  • Frederico Gaia Costa da Silva,
  • Hiroki Shichi,
  • Naoko Imagawa,
  • Naoki Yamamoto,
  • Yuma Motomura,
  • Yuka Oi-Yo,
  • Yuriko Sasaki,
  • Masaki Suzuki,
  • Shin Urai,
  • Hironori Bando,
  • Masaaki Yamamoto,
  • Michiko Takahashi,
  • Genzo Iguchi,
  • Maki Kanzawa,
  • Takashi Aoi,
  • Shozo Yamada,
  • Hidenori Fukuoka

摘要

Purpose

Personalized therapy in acromegaly is limited by interindividual variability in drug responses and the lack of robust markers predicting tumor shrinkage, rather than biochemical control alone. To test whether ex vivo drug-induced viability changes in patient-derived 3D cultures (Pd3D) of GH–secreting pituitary adenomas reflect tumor cell-intrinsic pharmacological sensitivity and align with established clinical predictors.

Methods

Spheroid-based Pd3D cultures were established from 27 patients with acromegaly. Cultures were exposed to octreotide, cabergoline, pasireotide, or vehicle control. We assessed cell viability changes; sample-level responder status (viability reduction vs vehicle, p < 0.05); and associations between responder status and known predictive markers, including clinical characteristics, MRI findings, dynamic drug tests, and pathological features. In 6 cases, AI-based digital image analysis quantified pre- and post-treatment SSTR2 expression in liquid-based cytology (LBC).

Results

All agents modestly reduced median cell viability (84–86%, p < 0.05), with responder rates of 33–40%. Concordance with established predictors was observed: octreotide responders correlated with T2 hypointensity (88% vs 44%, p = 0.04); cabergoline with positive bromocriptine tests (100% vs 45%, p = 0.03); and pasireotide with sparsely granulated patterns (64% vs 19%, p = 0.04). AI-based dynamic analysis demonstrated that ex vivo responders showed relatively stable SSTR2 expression after treatment, whereas nonresponders exhibited marked depletion.

Conclusion

Spheroid-based Pd3D ex vivo viability assays revealed modest but significant cohort-level effects and sample-level concordance with clinical predictors, suggesting its potential utility as an exploratory model. Additionally, AI-based quantification of SSTR2 dynamics captured functional receptor shifts.